Helixgate https://validator.w3.org/feed/docs/rss2.html Home Opinion: The podcast telling the stories behind Ambien, Ozempic, EpiPens, and other game-changing drugs Sanofi’s immunology reckoning; Lilly acquires in vivo CAR-T biotech; RevMed’s ‘Herceptin moment’; and more Thermo Fisher sees higher Q1 earnings amid strong biopharma demand AI Learns to Predict Breast Cancer Risk from How Single Cells Respond to Pressure Single-Cell Atlas of the Prenatal Brain Reveals How Down Syndrome Reshapes Development STAT+: FDA to speed up review of three psychedelics as mental health treatments STAT+: A biotech VC on what Eli Lilly saw in a struggling cancer startup for $3.2B FDA unveils three psychedelic-focused commissioner vouchers STAT+: Utah medical board calls for immediate suspension of state’s AI doctor experiment STAT+: Up and Down the Ladder: The latest comings and goings Sanofi MS drug rejected in US gets an endorsement in Europe FDA awards priority vouchers to 3 undisclosed companies for investigational psychedelics Compass, Usona and Transcend score FDA national priority vouchers amid Trump administration’s psychedelic push Avalyn plots $182M IPO; WHO prequalifies Novartis’ malaria drug Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelics Pfizer culls early PD-L1 asset after series of clinical wins, deals in cancer A CAR-T biotech’s dramatic turnaround, and drugmakers’ tactics to drive more scripts AI in Oncology Takes Off, Tackling HIV and Liver Disease, Pharma’s Recent Gains International childhood vaccine campaign grows BioSpace elevates journalism as biopharma evolves in the Trump era Enabling In Vivo Lentiviral Therapies: Manufacturing Strategies to Improve Purity, Scalability, and Clinical Readiness STAT+: Trump celebrates closing first round of drug pricing deals, promises more ahead FDA approves Regeneron’s hearing loss gene therapy Nancy Cox, a CDC veteran and a stalwart in global flu research, dies at 77 Exclusive: UC Berkeley startup bets on jumping genes for GLP-1 gene therapy CRISPR Base Editing Repairs Hard-to-Treat Cystic Fibrosis Mutation in Cell Models Sanofi’s tolebrutinib gets CHMP backing for certain MS patients despite FDA rejection Regeneron finally joins Trump’s drug pricing push while notching landmark approval Pfizer’s strategy chief Andrew Baum steps down; Helus Pharma swaps out CEO after two months Daiichi Sankyo postpones annual results, stock dips Psychedelics get a boost from the White House Opinion: Prasad’s FDA exit good for rare diseases but new CBER head must repair eroded trust FDA approves Regeneron’s hearing loss gene therapy Otarmeni Substance use disorder biotech Tempero to close after earlier ‘serious’ safety event Heart’s beat may help it beat cancer, mouse research suggests Novartis’ radioligand therapy Lutathera could soon face generic competition STAT+: Sanofi MS drug gets positive review in Europe following FDA FDA approval of Regeneron’s hearing loss gene therapy breaks barriers Regenerative Medicine: Promise, Hype, and What Actually Works Drugmaker AbbVie chooses North Carolina for $1.4B manufacturing campus AACR 2026 Video Update: Cancer Research Edges Toward an AI-Driven Era Amneal inks $1.1B Kashiv buyout to pursue biosimilar market leadership Daiichi Sankyo shares slip after delaying annual earnings report Opinion: Dropping the flu vaccine requirement puts U.S. military readiness at risk STAT+: CMS, FDA team up to fast-track reimbursement for breakthrough devices Japanese Pharma Companies Turning to CDMOs Earlier in Product Life Cycle David Reese to retire from Amgen Regeneron ushers in new genetic medicine era with groundbreaking gene therapy approval This week in Drug Discovery (20 – 24 April)